Clostridioides difficile infection (CDI) remains a significant clinical challenge both in the
management of severe and severe-complicated disease and the prevention of recurrence …

This clinical practice guideline is a focused update on management of Clostridioides difficile
infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for …

Abstract Scope In 2009, the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) published the first treatment guidance document for Clostridioides …

Clostridioides difficile remains a problematic pathogen resulting in significant morbidity and
mortality, especially for high-risk groups that include immunocompromised patients. Both the …

Guidelines for the diagnosis and treatment of Clostridioides difficile infection have recently
been updated. Risk factors include recent exposure to health care facilities or antibiotics …

Clostridioides difficile infection (CDI) is a common cause of diarrhea in both inpatient and
outpatient settings. The last few years have seen major changes in the treatment spectrum of …

Purpose We aimed to evaluate the efficacy of different antibiotic regimens for the treatment
of Clostridioides difficile infection (CDI) with regard to the CDI episode number and disease …

Background Current practice guidelines favour fidaxomicin over vancomycin and exclude
metronidazole from the recommended standard regimen for Clostridioides difficile infection …

Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI)
have been updated. However, in addition to the clinical efficacy data, the drug of choice …

Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection
(rCDI). Its high cost could be determining its prescription to a different population than that …